BMO Capital Reiterates Mirati Therapeutics (MRTX) at Outperform on Latest Adagrasib Data, but "Need to See Additional Data from Amgen" to Understand Market Potential
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $80.00 price target on Mirati Therapeutics (NASDAQ: MRTX), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
